



**FOR IMMEDIATE RELEASE**

**Selexis to Collaborate with Alpha Biologics on Mammalian Cell Line Development**

*- Alpha Biologics to use Selexis' SURE Technology Platform to Develop  
Therapeutic Proteins for Pre-Clinical, Phase I and II Clinical Trials -*

Geneva, Switzerland – July 10, 2006 – Selexis SA, a Swiss-based biotechnology company specializing in high yield and stable cell line development for therapeutic proteins, announced today that it has entered into a cooperative agreement with the Malaysian-based contract manufacturer, Alpha Biologics Sdn Bhd, to develop cell lines using the SURE technology platform. Under the agreement, Alpha Biologics will have access to Selexis' SURE engineered cell lines and expertise.

The SURE technology platform enables fast, stable and high yield cell lines that produce proteins and antibodies for a rapidly growing class of medicines known as biopharmaceuticals.

"We believe the SURE technology platform will provide significant benefits to Alpha Biologic's customers," said Dr. Igor Fisch, CEO, Selexis SA. "Our SURE engineered cell lines will help Alpha Biologics deliver therapeutic proteins for use in pre-clinical, Phase I and II clinical trials to their customers significantly faster and more cost effectively. In addition, this agreement is the first step of our strategy to enter into the Asian market."

Selexis' SURE technology platform, which includes the patented MARtech™, is a unique technology that improves the speed, yield and stability of production cell lines used for therapeutic protein manufacturing. Based on proprietary human MAR (Matrix Attachment Region), MARtech™ enables cell population generation in just four weeks (after transfection) and stable cell line development in five weeks (after transfection to first round of cell cloning). Additionally, MARtech™ has been found to significantly increase recombinant protein expression in mammalian cells in suspension and in serum-free up to twenty fold.

- more -

SELEXIS EUROPE  
18 chemin des Aulx  
1228 Plan-les-Ouates  
Switzerland

T +41 (0)22 308 93 60  
F +41 (0)22 308 93 61

SELEXIS USA  
655, Montgomery St. STE 540  
94111 San Francisco  
USA

T +1 415 273 51 41  
F +1 415 837 32 04

“The SURE technology platform’s ability to generate high yield cell lines with significantly higher production and secretion rates in just a few weeks will help us deliver protein therapeutics to our customers faster, thereby helping to achieve Alpha’s objective of reducing the time and cost of our clients’ drug development programmes” said Simon Saxby, CEO, Alpha Biologics. “Additionally, by removing the need to license several expression and cell line technologies, our customers will realize further significant cost advantages.”

#### **About Selexis**

Selexis is a privately held biotechnology company dedicated to the development of innovative technologies and expert services. Selexis offers comprehensive and rapid solutions for the development of stable, high yield mammalian cell lines used in recombinant protein manufacturing. The Company’s unique SURE technology platform, which includes Selexis’ forth generation patented MARtech™, reduces traditional cell line development (DHFR) from 12 months to 5 weeks (after transfection to isolating cell clones) without any change in the scale-up process. For more information please visit <http://www.selexis.com>

#### **About Alpha Biologics**



Alpha Biologics is a privately held cGMP compliant contract manufacturer of mammalian cell secreted biologics for use in pre-clinical and Phase I - III clinical trials for the global market. Alpha specializes in master and manufacturing cell bank generation, process development and cGMP production and purification in a new state-of- the-art 5,000m<sup>2</sup> US FDA design reviewed facility. For more information please visit <http://www.alphabiologics.com>

## Selexis SA Enters Cooperative Agreement with Alpha Biologics

Page 3

*This news release contains forward-looking statements that involve a number of known and unknown risks and uncertainties. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. These statements are only predictions and actual events or results in future periods may differ materially from what is currently anticipated. In particular, we cannot assure you that we will be able to successfully develop or commercialize products based on our technology, particularly in light of the significant uncertainty inherent in developing drug delivery products, conducting clinical trials and obtaining regulatory approvals, that our technologies will prove to be safe and effective, that our joint ventures or our collaborations with other companies in the U.S. and abroad will successfully develop products or become profitable, that our business strategy will be successful or that we will be able to carry out our plans for 2007.*

*MARtech™ is a trademark of Selexis, SA.*

### **MEDIA CONTACT:**

Robert Meister  
602-953-1716  
[robert.meister@selexis.com](mailto:robert.meister@selexis.com)

### **ALPHA BIOLOGICS CONTACT:**

Simon J. Y. Saxby  
44(0)1223 370195  
[simon.saxby@alphabiologics.com](mailto:simon.saxby@alphabiologics.com)

### **MORE INFORMATION:**

EUROPE  
Igor Fisch, Ph.D.  
41 (0)22 308 93 60  
[igor.fisch@selexis.com](mailto:igor.fisch@selexis.com)

UNITED STATES  
Cori Gorman, Ph.D., M.B.A  
415-273-5141  
[cori.gorman@selexis.com](mailto:cori.gorman@selexis.com)

# # #